Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03996850 · ClinicalTrials.gov registry record
SPECT/CT for the Characterization of Renal Masses
A clinical trial of Kidney Neoplasm and Renal Mass, sponsored by Jonsson Comprehensive Cancer Center.
- Active
- Registry status
- 102
- Enrollment target
- 1
- Study location
NCT03996850 is a study of Kidney Neoplasm and Renal Mass that is active but no longer recruiting, run by Jonsson Comprehensive Cancer Center. The registered enrollment target is 102 participants, below the 192-participant average among 4 other Kidney Neoplasm trials with a reported enrollment target (47% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03996850, a study of Kidney Neoplasm and Renal Mass, is active but no longer recruiting, sponsored by Jonsson Comprehensive Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- 102 participants
- Enrollment target
- 1
- Study location
Study Summary
This trial studies how well technetium Tc-99m sestamibi single-photon emission computed tomography/computed tomography (SPECT/CT) works on clinical decision making in patients with kidney tumors. Diagnostic procedures, such as technetium Tc-99m sestamibi SPECT/CT may be a less invasive way to check for kidney tumors.
Conditions Studied
Interventions
- PROCEDURE Computed Tomography
- OTHER Questionnaire Administration
- PROCEDURE Single Photon Emission Computed Tomography
- RADIATION Technetium Tc-99m Sestamibi
Study Locations (1)
California
- UCLA / Jonsson Comprehensive Cancer Center - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 102 participants |
| Start Date | 2018-12-07 |
| Est. Completion | 2027-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03996850
The ClinicalTrials.gov registry entry for NCT03996850 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 102 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 192-participant average among 4 other Kidney Neoplasm trials with a reported enrollment target (47% lower). The listed sponsor is Jonsson Comprehensive Cancer Center, which has 321 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Kidney Neoplasm appearing as the primary indexed condition, and to 4 interventions - of which Computed Tomography is the first listed.
NCT03996850 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT03996850 about?
NCT03996850 is a clinical study titled "SPECT/CT for the Characterization of Renal Masses". This trial studies how well technetium Tc-99m sestamibi single-photon emission computed tomography/computed tomography (SPECT/CT) works on clinical decision making in patients with kidney tumors. Diagnostic procedures, such as technetium Tc-99m sestamibi SPECT/CT may be a less invasive way to check ...
What is the current status of trial NCT03996850?
This trial is currently active not recruiting. The enrollment target is 102 participants. The study started on 2018-12-07. Estimated completion is 2027-12-31.
What conditions does trial NCT03996850 study?
This clinical trial studies the following conditions: Kidney Neoplasm, Renal Mass.
What interventions are being tested in trial NCT03996850?
The interventions under investigation include: Computed Tomography (PROCEDURE), Questionnaire Administration (OTHER), Single Photon Emission Computed Tomography (PROCEDURE), Technetium Tc-99m Sestamibi (RADIATION).
Who is sponsoring clinical trial NCT03996850?
This trial is sponsored by Jonsson Comprehensive Cancer Center, which has 321 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03996850 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Kidney Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The Delayed Intervention and Surveillance for Small Renal Masses (DISSRM) Registry
RECRUITING
-
Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC
RECRUITING · Phase 2
-
Hyperpolarized 13C Pyruvate MRI Scan in Predicting Tumor Aggressiveness in Patients With Renal Tumors
ACTIVE NOT RECRUITING · Phase 2
-
A Phase I Study of Infusional Chemotherapy With the P-Glycoprotein Antagonist PSC 833
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.